Archive for the 'NIH funding' category

Unfunded Overhead

Jun 06 2013 Published by under Careerism, NIH, NIH Careerism, NIH funding

It struck me today

thanks to the referenced comment from Jim Woodgett that we've never really had a discussion of unfunded overhead situations, despite several discussions of overhead rates in the ongoing effort to determine TheRealProblemTM with NIH budgets these days. It is worth bringing up, particularly for anyone who might be job seeking or negotiating in the near future. As we continue, you'll see what you need to ask about, and what you need to get in writing along with your job offer.

As a brief introduction the overhead (or Indirect Costs; IDC) associated with a research grant award is the amount that disappears into the University, research institution (or what have you) instead of going into the PI's account to spend.

When it comes to federal awards from the NIH (and some other agencies beloved of my Readership) the IDC rate varies across the Universities, research institutes and varied other applicant institutions. For discussion's sake, I'll throw out that the general rate for larger public Universities is about 56%. Smaller (private) Universities and not-for-profit research institutes tend to have higher ones with overhead rates of over 80% not uncommon. Rumors abound of 100% overhead rates but I've not directly seen one of those myself. To my recollection. This research crossroads site used to have a handy database of the federally-negotiated overhead rates but it has been down for some time now and I suspect it is defunct. I don't know where they were scraping their data from but presumably these overhead rates are public info.

There are numerous non-federal sources of funding that a given PI might see as appropriate to pursue for her laboratory. Contracts with biotech or Big Pharma companies. Larger or smaller disease focused foundations (American Heart, Michael J Fox). Less-focused foundations (like Bill and Melinda Gates Foundation). Local philanthropic donors. State foundations or funds (like those diverted from tobacco or alcohol taxes). In many, if not most, cases these funding streams do not wish to pay your University the federally-negotiated overhead rate.

The differential can be large. Such as a foundation that will pay 10% maximum...and your federal rate sits at 70%. Perhaps a donor doesn't want to pay any overhead at all and expects the full donation to go into the research lab's coffers.

The ways that Universities and research institutions deal with this issue varies considerably. Across institutions, of course. But also within an institution depending on the money source, the amount of funding involved, the identity of the PI, etc.

The best case scenario for PIs is the institution that doesn't care. Money is money and....they'll take it. I've heard rumor of such things but it is fantasy as far as I am concerned.

What is more common is that the University has a way to cover the "unfunded overhead" situation to make it appear that the full federally negotiated rate is being applied to each and every grant of consequence*. Sometimes this is accomplished through the mumbo-jumbo of money being fungible and the University simply using their endowment proceeds or some other source of funds not easily connected to a grant to "cover" the overhead. This is good, if you can get it. That is, if your University has a default, no-questions-asked way to do this for a given source of grant support. That's a supportive place to be.

Considerably less-good is the situation where the PI is supposed to "cover" this for herself. Now sometimes it is the case that the Chair of the Department covers it through a slush fund and, obviously, this would be a more limited pool of money. Consequently, the Chair has to balance who gets the slush. This leaves a lot of room for shenanigans having to do with departmental politics. A lot of room for problems based on how many faculty are trying to tap this pot of slush money in a given year. This is why you, as a prospective new hire, need to ask how these situations are covered and get as much in writing as you can.

There are two remaining horrible options which I hesitate to rank.

Some Universities will pull the overhead out of the new-hire's startup funds. That's a dicey game for a new faculty member to play. It might be worth it, it might not. Why would it be worth it? Well, that startup is a fixed, nonrenewable pool of money that is supposed to get you launched, right? This means, in essence, to help you secure a grant. Having grant funding awarded to your lab is a good thing and catapults you into the "funded investigator" category. Depending on the size of it, your use of startup to secure that award, instead of continuing the uncertain game of generating more preliminary data, may be advisable. You just have to look at the leverage that contributing startup to the unfunded overhead will give you.

Some places (and here I find the very high overhead, small not-for-profit research institutes to raise their heads) simply refuse to let faculty (even new hires) apply for anything that doesn't come with full overhead.

Yes, this seems an unbelievably stupid policy and a way to cripple the prospects of your newly-hired faculty, but there you have it.

For anybody on the job market that is reading this, the conclusions are clear. If the unfunded overhead policies of your prospective institutions are not handed to you when you visit, ask. Determining what grants you will and will not be allowed to apply for in your first few years (or across your career) should not be left up to the (entirely logical) assumption that any grant available is attractive to your University.

ETA: A comment from Jim Woodgett

In essence, NIH subsidizes those agencies and philanthropists that don't allow or who restrict overhead.

reminded me I forgot to address why the Universities are doing this. My assumption is that if the federal negotiators thought this statement sufficiently true, they would lower the IDC rate for that University. As I said, my assumption. I've never been able to get an institutional official to verify this directly though.

Additional reading: Cost principles, Proflike Substance on what overhead pays for.
__
*there can be blanket exceptions for trainee fellowships or exclusions based on an upper limit on the "award".

Share

25 responses so far

basic research wackaloonery

May 28 2013 Published by under NIH, NIH Careerism, NIH funding

Here's the thing. Yes, it is true that health advances are built on a firm foundation of basic research. So the National Institutes of Health are going to require a lot of basic research get done to fulfill their fundamental mission of improving public health.

When we talk about 'translational' research, the fundamental concept under the tritely dismissible buzzwording is solid reality. We need to go from basic science, basic discovery to applications with human patients. And that takes a lot of people, a lot of time, a lot of investment and a LOT of blind alleys. We know this.

But you can get different people with different attitudes working on "basic" research. And as far as I am concerned there is no problem having a bias against the ones who proudly and arrogantly proclaim that they would never dirty their high-falutin' "basic research" interests with anything so pedestrian as a potential application.

Screw em.

I'd rather award the grants to those basic scientists who have some recognition that they are being paid by the taxpayers to solve health problems, not to entertain themselves with faked up model organism systems that will never translate. Or to engage in sub-sub-sub-field arguments about how many proteins fit on the head of a nanobot pin. Or to be so interested in the "get", i.e. a Nature, Cell or Science paper accepted, that they will fail to publish all sorts of data that they have generated on the public dime.

Share

61 responses so far

Overheard at a Vendor Fair

May 17 2013 Published by under Careerism, NIH, NIH Budgets and Economics, NIH funding

"Oh, we know nobody is actually going to buy anything. We're just here to make connections with postdocs for down-the-road."

Share

One response so far

Show me the money, Francis!

May 15 2013 Published by under NIH, NIH Budgets and Economics, NIH funding

Later on Drugmonkey, we will be discussing this.


Later......

So this linked set of slides describes analysis of the DP1 award mechanism. Said DP1 was created to "address concerns that high risk, visionary research was not being supported due to the conservative nature of existing NIH funding mechanisms". So, instead of gee, I dunno, FIXING this problem they did what they always do and created a new mechanism.

It was supposed to be creating review:

Based on the premise that “Person Based” application and review processes would reward past creativity and encourage innovators to go in new directions

The DP1 was open to all career stages and took a 5 page essay to describe how awesome and visionary you are. There was no requirement to submit a budget and the awards were for $500k direct costs for 5 years.

This analysis compares the DP1 awardees 2004-2006 with 1) matched R01s (on PI stage and background, topic, local institution, same time frame. combined budget was 50% of the DP1 Pioneers) 2) Random all-NIH portfolios of same total costs (but not matched on other PI characteristics), 3) HHMI investigators from 2005 competition ($600K direct costs, reappointment rate is 80% after 5 yrs and HHMI averages 15 yrs duration total) and 4) the DP1 applicants that weren't selected.

As you will see from the slides, there is tremendous degree of overlap in the distribution of outcome measures that they are using. Tremendous. So mean differences need to be taken with a huge dose of "yeah but all is never held completely equal". Still

1) DP1 produce the same number of publications per dollar as matched R01s, in higher Scimago ranked journals and the awards have a higher h-index rating (DM- interesting to give a grant award an h-index isn't it?). "experts assess DP1 research as having more impact and innovation".

Yeah. Big whoop. You select a group for innovation and awesomeness, take them off the cycle of grant churning by handing them a 2-3 grant award all at once (for the cost of a 5 page essay and a Biosketch, plus some big swanging reference letters) and they look incrementally better. See overlap, they aren't awesomely better. Compared with labs unselected, fighting the regular grant wars and with half the money. Color me severely underimpressed by this analysis of the DP1 program. All it does is tell us to give more people the same damn deal. One might even suggest this deal approximates the deal that many of our older colleagues had in effect for much of their careers when success rates for competing continuations from established investigators was north of 45%.

2) Now you match these Pioneers on R01 direct costs there is no difference in pubs or cites. Impact factor is higher for the Pioneers but the h-index doesn't differ. Experts assess Pioneers as higher impact and innovation.

These matched direct-costs PIs were in lower rank institutions (by some margin) and were longer past their terminal degrees. Since there was no matching on topic, institution or background characteristics I'm going to suggest that h-index really comes to the fore for this analysis. You simply cannot compare glamour chasing molecular eleventy labs with, say, clinical operations. There are too many differences in citation practices, GlamourHumping and what is conventionally viewed as "high impact". h-index gives us a better approximation of real impact. So meh on this analysis too.

3) HHMI folks published more papers, had more citations but not if one accounted for the direct-cost differential. HHMI folks published in higher impact journals but the h-index was the same. Experts assess the impact and innovation the same. Interestingly (to me) the HHMI folks were closer to their terminal award than the mean of the other groups. The spread was tighter, this is by design of the HHMI but I guess I was a little surprise the DP1 time-since-degree was so diverse. Institutional rankings did not differ between HHMI, DP1.

Snoooooore......

4) The only loser-finalists data reported was on the Institution rankings and the time-since-degree which didn't differ from the successful DP1 awardees.

Very frustrated on this one! An absolutely critical comparison group in my view. How did these folks do? Did they get other funding? Did they suck in terms of productivity? Did they get their money anyway and compete successfully?

The overall conclusion slide nails it in the first bullet point. We really don't need to go on from:

It appears that higher funding leads to higher portfolio‐level impact.

Look, I'm not saying that other factors don't contribute. But this is an "all else held equal" analysis. Or an attempt at it. If you match the PIs on their approximate fields, type of work, background, local institutions, etc and give them the same amount of research support, they do the same. Even the much-vaunted HHMI sinecure funding (at approximately 1 R21 or half a R01 greater value per year vs DP1) which can be expected to last for 15 year of programmatic support doesn't make a radical difference! Note that the DP1 doesn't come with any such guarantee of longer-term funding for the PI. S/he knows full well that they are right back in the hunt 2-3 years down the road. So I guess it is worth hammering the final bullet point:

DP1 vs HHMI: likely not attributable to flexibility of research, or riskiness of ideas, but may be due to funding level and stability, differences in PIs, or differences in areas of science.

Share

29 responses so far

NIGMS FY2012 Funding Outcome Data

May 07 2013 Published by under NIH, NIH funding

h/t PhysioProf

Share

27 responses so far

BRAIN Initiative

I just watched part of a live stream [current link] of some meeting to brainstorm about what the $100M BRAIN Initiative should be.

What at a disaster.

Bunch of reinforcement that this is all about a bunch of senior dudes (mostly male dewds too) in neuron-recording neuroscience who used to make out like bandits from NIMH support. Now that we've undergone a long slide in funding levels and Insel's push to translational-ize the NIMH portfolio has gained the upper hand...these folks are struggling to get grants. JUST. LIKE. THE. REST. OF. US.

and they can't come up with anything amazing by themselves so they need $100M cash money to build some new recording tools to....you guessed it, record some more neurons.

Outside of the regular grant process because they find it hard to compete these days. JUST. LIKE. THE. REST. OF. US.

I have a proposal. Let's throw down, what, maybe $1M to record symposia and meetings of these people for the next year. Maybe have a few more of these summits. And after all that, if they've come up with some thing that is ACTUALLY NEW AND INTERESTING then and only then do we give them the $99M.

UPDATE: Permalink

Share

32 responses so far

Thought of the day

May 06 2013 Published by under NIH funding, Postdoctoral Training

Why the heck am I still getting "please get me out of [insert non Western country here]" postdoc inquiries? Haven't they heard our funding situation is horrible in this country?

Goodness gracious.

Share

11 responses so far

Rubber....meet the road. NIH Grant edition

May 06 2013 Published by under NIH, NIH Budgets and Economics, NIH funding

It is all very well to read the tea leaves and to make inferences from what Program Officials are telling you, published paylines, the gossip at writedit's blog and your anguished colleagues.

But nothing like a little judicious searching at RePORTER and / or a review of SILK listings to let you know just what your favorite handful of ICs are up to.

Happy browsing.

Personally, my biggest takeaway is that I should have ignored all the doom and gloom about R21s last year and submitted a few of them.

Share

7 responses so far

Harvard to close their New England National Primate Research Center

Apr 25 2013 Published by under Animals in Research, NIH, NIH Careerism, NIH funding

Harvard has decided not to seek to renew NIH support for their New England National Primate Research Center, established by Congress in 1962. The Center has operated with a so-called "base grant" from the National Institutes of Health underpinning the not-inconsiderable costs of housing thousands of nonhuman primates and the usual grab bag of investigators' independent sources of funding. The NENPRC site lists an impressive series of accomplishments.

First unambiguous evidence that AIDS is caused by a virus.
Discovery of Simian Immunodeficiency Virus (SIV) and development of first animal model of AIDS.
Original demonstration that vaccine protection against AIDS is theoretically possible.
Discovery that a gene product of the AIDS virus activates lymphocytes necessary for disease progression.
Identification of therapeutic genes that can prevent infection of cells by the AIDS virus.
First demonstration that protective genes introduced into blood stem cells can block HIV or SIV infection.
Discovery of primitive blood stem cells lacking CD34 and their implications for bone marrow transplantation
Isolation of type-D retroviruses as major causes of illness and death in macaques.
Discovery of the oncogenic herpesvirus, Herpesvirus saimiri.
Discovery of a nonhuman primate virus closely related to the human Kaposi's sarcoma-associated herpesvirus.
First nonhuman primate models of colon cancer and inflammatory bowel disease.
Evidence leading to the use of hydroxyurea to treat sickle cell anemia.
Discovery of stunned myocardium and its role in myocardial ischemia.
Discovery of cellular organization and critical period for development of the visual cortex.
First unambiguous evidence for the addictive properties of nicotine.
Identification of major risk factors in self-injurious behavior.
First animal model for progressive neurodegeneration in Parkinson's disease.
Development of improved brain imaging techniques for early diagnosis of Parkinson's disease.
Development of novel cellular and pharmacological strategies for treatment of Parkinson's disease.
First survey of distribution of cocaine binding sites in primate brain.
Identification of the dopamine transporter as a principal target for cocaine in the brain.
First nonhuman primate model of drug relapse.
Development of novel drug classes to treat cocaine addiction and other brain dopamine disorders.

Most of the news reporting has focused on a series of lapses in the care of nonhuman primate subjects, leading to several deaths. I cannot comment on the degree to which this situation reflected lapses in the system, but clearly Harvard was undergoing major corrective measures. The news accounts describe situations which seem to me to be procedural lapses that have relatively straightforward fixes. Nothing appears to be systematically unfixable...again, going by the news accounts.

The Harvard Medical School press release is slightly more instructive, however.

The decision to conclude NEPRC operations follows a two-year period during which the Center leadership successfully addressed operating issues with input from the NIH and other governing agencies. The process resulted in new procedures that have significantly strengthened the Center’s day-to-day activities and that can serve as a model for other institutions throughout the country. Many of those changes carried additional costs, and HMS will continue to make investments in the Center to ensure ongoing compliance with all federal regulations.

Right? So the problems were fixable and they'd been investing in fixing them for two years. "Additional costs", eh? Well, no biggie if the investment is good.

But what has happened in the past several months, hmm? The sequester. The Continuing Resolution for FY2013. Obama's budget request for FY2014. None of this is good news. If you look at the NENPRC as effectively a small, soft-money research institute funded in large extent by federal grants (and let's face it, partnering with for-profits isn't going that well for academia right now either) then its prospects are pretty dim. Look at the situation through the lens of Return on Investment and everything becomes clear.

As they weighed whether to renew the base grant from the NIH, HMS leaders made a strategic decision based on a review of the long-term academic benefits and the financial cost of continuing to operate the NEPRC.

“Deciding how to best assign our limited resources is not unique to HMS,” said Jeffrey S. Flier, Dean of the Faculty of Medicine of Harvard University,

also...


Driving the decision was the fact that the external funding environment for scientific research has become increasingly challenging over the past decade. Recent funding pressures have added uncertainty to this already-challenging fiscal context. As Harvard Medical School leadership evaluated the long-term need to use its resources in the most effective manner across all of its missions, they came to the conclusion that winding down the operations of the NEPRC was more beneficial to the School than investing further resources in maintaining and renewing the NEPRC grant.

So yeah, this looks from the outside like a small, specialized research institute closing down due to the NIH funding situation to me.

Maybe I have NIH grant myopia but this is the way it looks.

I am reviewing some of the claims made about their listed accomplishments and going back to the original papers, where I can deduce them. In a few areas that I am familiar with....man. Straight up. These are valid claims, even if we recognize that no science breakthrough arrives entirely by itself. And more importantly, particularly when it came to the early days of AIDS, I am having trouble imagining how progress could have been made so rapidly without one of the National Primate Research Centers. They really do seem to serve a unique function in the NIH / US Federal extramural research enterprise and it would be a shame if this was merely the lead indicator in shuttering the whole program.
__
Disclaimer: I have professional acquaintances that work at NENPRC. I am disturbed that they are losing their jobs and I do hope that they get snapped up by some other University.

Share

39 responses so far

NIAID publishes their FY2013 paylines

Apr 19 2013 Published by under NIH, NIH Budgets and Economics, NIH funding

NIAID is one of the NIH ICs that actually publishes a payline. According to their website, as of April 19 the R01s from experienced investigators will have a payline of 8 percentile. The payline for new investigators will be 12 percentile. By way of comparison these were 10%ile and 14%ile in the prior two Fiscal Years for NIAID.

Mechanisms such as the R03, R21 and R15 will have to get a 20 overall impact score, or better, to fund but these are still listed as "interim" criteria.

So from a statistical basis, you need to have put in 13 proposals to NIAID this year in order to have a fighting chance to get one.

Lovely.

Share

45 responses so far

Older posts »